Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danicopan - Alexion AstraZeneca Rare Disease

Next Previous
X
Search
Drug Profile

Danicopan - Alexion AstraZeneca Rare Disease

Alternative Names: 4471; ACH-0144471; ACH-4471; ACH-CFDIS; ALXN 2040; Voydeya

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Achillion Pharmaceuticals
  • Developer Achillion Pharmaceuticals; Alexion AstraZeneca Rare Disease
  • Class Amides; Anti-inflammatories; Antianaemics; Eye disorder therapies; Halogenated hydrocarbons; Indazoles; Pyridines; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Membranoproliferative glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Paroxysmal nocturnal haemoglobinuria
  • Phase II Dry macular degeneration
  • Discontinued Haemolytic uraemic syndrome; Membranoproliferative glomerulonephritis

Most Recent Events

  • 23 Jul 2024 Registered for Paroxysmal nocturnal haemoglobinuria (Adjunctive treatment) in Canada (PO)
  • 07 Jun 2024 Alexion Pharmaceuticals plans a phase III trial for Paroxysmal nocturnal hemoglobinuria (In adolescents, Treatment-experienced, Adjunctive therapy) (PO), in August 2024 (NCT06449001, D7332C00006)
  • 25 Apr 2024 Registered for Paroxysmal nocturnal haemoglobinuria (Adjunctive treatment) in European Union (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top